Search results
Results from the WOW.Com Content Network
1 mg 1x/3–4 weeks: 3 mg 1x/3–4 weeks: 5 mg 1x/3–4 weeks Estradiol benzoate: 0.5 mg 1x/week: 1 mg 1x/week: 1.5 mg 1x/week SC implant: Estradiol: 25 mg 1x/6 months: 50 mg 1x/6 months: 100 mg 1x/6 months Footnotes: a = No longer used or recommended, due to health concerns.
[126] [127] [124] Women who are not on a birth control pill or hormone therapy have a risk of VTE of about 1 to 5 out of 10,000 women per year. [ 126 ] [ 127 ] [ 116 ] [ 124 ] In women taking a birth control pill containing ethinylestradiol and a progestin, the risk of VTE is in the range of 3 to 10 out of 10,000 women per year.
Medications and dosages used in transgender women [1] [2] [3] [4] [5] [a]; Medication Brand name Type Route Dosage [b]; Estradiol: Various: Estrogen: Oral: 2–10 mg ...
Estradiol/dydrogesterone (E2/DYD), sold under the brand name Femoston among others, is a combination of estradiol (E2), an estrogen, and dydrogesterone (DYD), a progestin, which is used in menopausal hormone therapy, specifically to treat and prevent hot flashes and osteoporosis, in postmenopausal women.
Estradiol levels after an intramuscular injection of 10 mg estradiol valerate in oil, Climacteron (150 mg testosterone enanthate, 1 mg estradiol benzoate, 7.5 mg estradiol dienanthate in oil), and control group in 20, 11, and 11 ovariectomized women, respectively. [128] Assays were performed using RIA. [128] Source was Sherwin et al. (1987). [128]
In postmenopausal women, a dosage of 1 mg/day oral micronized estradiol has been found to produce circulating concentrations of 30 to 50 pg/mL estradiol and 150 to 300 pg/mL estrone, while a dosage of 2 mg/day has been found to result in circulating levels of 50 to 180 pg/mL estradiol and 300 to 850 pg/mL estrone. [15]
Estrone (E1), sold under the brand names Estragyn, Kestrin, and Theelin among many others, is an estrogen medication and naturally occurring steroid hormone which has been used in menopausal hormone therapy and for other indications.
A 2012 meta-analysis estimated that the absolute risk of VTE is 2 per 10,000 women for non-use, 8 per 10,000 women for EE and levonorgestrel-containing birth control pills, and 10 to 15 per 10,000 women for birth control pills containing EE and a third-or fourth-generation progestin such as desogestrel or drospirenone. [47]